About Repros
Company Overview
Board of Directors and Management
Pipeline
Proellex
®
Anemia Associated with Uterine Fibroids
Uterine Fibroids
Endometriosis
Publications
Androxal
®
Male Fertility Maintenance/Improvement
Metabolic Syndrome
Publications
Clinical Trials
Proellex® Endometriosis (ZPE-201)
Proellex® PK Bridging (ZP-002)
Proellex® Safety and PK (ZP-003)
Investors & Media
Events, Presentations and Webcasts
Repros in the News
Major Holders
Analyst Coverage
SEC Filings
Corporate Governance
Contact Us
May 8, 2008
Repros to Report First Quarter 2008 Financial Results
March 31, 2008
Repros Reports Interim Safety Results From Ongoing One-Year Open Label Study of Proellex® in the Treatment of Uterine Fibroids
March 17, 2008
Repros Therapeutics Inc. Reports Fourth Quarter and Year End 2007 Financial Results and Provides Clinical Development Program Overview
March 13, 2008
Repros to Report Fourth Quarter and Full Year 2007 Financial Results on March 17, 2008
May 29, 2008
FBR 12th Annual Spring Investor Conference
May 14, 2008
Annual Meeting of Shareholders in New York City, NY
May 12, 2008
Repros Shareholder Update Conference Call
February 28, 2008
13th World Congress of Gynecological Endocrinology Symposium: Effects of Progesterone Receptor Modulators in Female Reproductive Health with Emphasis on the Endometrium
Terms of Use
© Repros Therapeutics Inc. All rights reserved.
2408 Timberloch Place, B-7
The Woodlands, Texas 77380
281-719-3400
281-719-3446 fax
